IP Library Granted Patent US 12,091,420
Granted Patent B2
US 12,091,420 · App. 18/376,159 · Granted Sep 17, 2024

SARS-COV2 main protease inhibitors

Inventors: Stephen E. Ammann (Foster City, CA); Xinpei Cai (San Mateo, CA); Eda Y. Canales (San Mateo, CA); Weng K. Chang (San Lorenzo, CA); Gregory F. Chin (San Francisco, CA); Henok H. Kinfe (Foster City, CA); Jessica L. Mckinley (Foster City, CA); Michael R. Mish (Foster City, CA); Devan Naduthambi (San Bruno, CA); Jason K. Perry (San Francisco, CA); Kevin X. Rodriguez (San Mateo, CA); Scott D. Schroeder (Union City, CA); Christopher J. Swank (San Mateo, CA); Joshua J. Van Veldhuizen (Seattle, WA)
Assignee: Gilead Sciences, Inc.
C07D495/04C07D401/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,091,420
App. No.
18/376,159
Granted
Sep 17, 2024
Kind
B2
Abstract

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Claims (41)

1. A compound selected from

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , which is

or a pharmaceutically acceptable salt thereof.

14. A compound selected from

15. The compound of claim 14 , which is

16. The compound of claim 14 , which is

17. The compound of claim 14 , which is

18. The compound of claim 14 , which is

19. The compound of claim 14 , which is

20. The compound of claim 14 , which is

21. The compound of claim 14 , which is

22. The compound of claim 14 , which is

23. The compound of claim 14 , which is

24. The compound of claim 14 , which is

25. The compound of claim 14 , which is

26. The compound of claim 14 , which is

27. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

28. A pharmaceutical composition comprising the compound of claim 14 and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: AMMANN, STEPHEN E.; CAI, XINPEI; CANALES, EDA Y.; CHANG, WENG K.; CHIN, GREGORY F.; KINFE, HENOK H.; LAZERWITH, SCOTT E.; MCKINLEY, JESSICA L.; MISH, MICHAEL R.; NADUTHAMBI, DEVAN; PERRY, JASON K.; RODRIGUEZ, KEVIN X.; SCHROEDER, SCOTT D.; SWANK, CHRISTOPHER J.; VAN VELDHUIZEN, JOSHUA J.
To: GILEAD SCIENCES, INC.
Reel/Frame 065403/0238 →
Continuity (8)
Continuation 18365919 · Aug 4, 2023
Provisional Application 63508350 · Jun 15, 2023
Provisional Application 63486156 · Feb 21, 2023
Provisional Application 63482750 · Feb 1, 2023
Provisional Application 63476359 · Dec 20, 2022
Provisional Application 63375522 · Sep 13, 2022
Provisional Application 63370629 · Aug 5, 2022
Related Publication 20240116946A1 · Apr 11, 2024
Cited By (1)
US 12,410,183